• Profile
Close

Breakthrough Clostridium difficile infection in cirrhotic patients receiving rifaximin

Clinical Infectious Diseases Mar 22, 2018

Reigadas E, et al. - The incidence and characteristics of Clostridium difficile infection (CDI) were assessed in patients with cirrhosis, especially in those who received rifaximin. Researchers noted a high percentage of CDI cases in cirrhotic patients receiving rifaximin, mostly owing to selection of rifaximin-resistant C. difficile strains. As per multivariate analysis, rifamycin therapy and ribotype 001 were relevant risk factors for having a rifaximin-resistant C. difficile strain.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay